Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight
- PMID: 3030900
- PMCID: PMC1432983
- DOI: 10.1136/gut.28.2.150
Optimum dosage of ispaghula husk in patients with irritable bowel syndrome: correlation of symptom relief with whole gut transit time and stool weight
Abstract
To determine the optimum dose of ispaghula husk in patients with irritable bowel syndrome (IBS) and to assess the correlation, if any between the relief in patients' symptoms and the whole gut transit time, and the increase in stool weight, a two part study was carried out. In part 1, 14 male patients were given ispaghula husk in increasing doses of 10 g, 20 g, and 30 g a day for a duration of 17 days each (14 days of study period + three days of stool collection). Ten patients completed the trial. The symptom score improved significantly with all the three doses of ispaghula. Both 20 g and 30 g doses of ispaghula were superior to the 10 g dose but there was no significant difference between the 20 g and 30 g doses. There was a significant (p less than 0.001) increase in the daily stool weight with 10 g dose of fibre with further significant increases with the 20 g and 30 g doses. A positive correlation was seen between the improvement in the symptom score and the increase in stool weight with the 10 g dose of ispaghula but not with the 20 g and 30 g doses. Whole gut transit time remained fairly constant throughout the study period and there was no relationship with either the dose of ispaghula, the alteration in stool weight, or the improvement in the patients symptoms. Ten patients completed part 2 of the study in which ispaghula husk was given in the same dose (10 g, 20 g, and 30 g) but in a random order and with a "washout" period of one week between individual doses. Again all the three doses of ispaghula produced a significant improvement in the symptoms; 20 g and 30 g doses were equally effective and both were significantly superior to the 10 g dose. Assessed individually, all the three symptoms improved significantly; improvement in constipation and pain abdomen was more pronounced than diarrhoea. It is concluded that the optimum dose of ispaghula husk in irritable bowel syndrome is 20 g per day. There is some correlation between the increase in stool weight and the improvement in symptom score but the whole gut transit time remains unchanged despite alterations in stool weight and patients' symptoms.
Similar articles
-
A comparison of mebeverine with high-fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study.Br J Clin Pract. 1990 Nov;44(11):461-6. Br J Clin Pract. 1990. PMID: 2177997 Clinical Trial.
-
Ispaghula therapy in irritable bowel syndrome: improvement in overall well-being is related to reduction in bowel dissatisfaction.J Gastroenterol Hepatol. 1990 Sep-Oct;5(5):507-13. doi: 10.1111/j.1440-1746.1990.tb01432.x. J Gastroenterol Hepatol. 1990. PMID: 2129822 Clinical Trial.
-
Double blind study of ispaghula in irritable bowel syndrome.Gut. 1987 Nov;28(11):1510-3. doi: 10.1136/gut.28.11.1510. Gut. 1987. PMID: 3322956 Free PMC article. Clinical Trial.
-
Tegaserod: a review of its use in the management of irritable bowel syndrome with constipation in women.Drugs. 2003;63(11):1101-20. doi: 10.2165/00003495-200363110-00013. Drugs. 2003. PMID: 12749744 Review.
-
Bran: may irritate irritable bowel.Nutrition. 1998 May;14(5):470-1. doi: 10.1016/s0899-9007(97)00498-x. Nutrition. 1998. PMID: 9614316 Review.
Cited by
-
Digestibility and bulking effect of ispaghula husks in healthy humans.Gut. 1994 Dec;35(12):1747-52. doi: 10.1136/gut.35.12.1747. Gut. 1994. PMID: 7829013 Free PMC article. Clinical Trial.
-
Chronic constipation in Rome IV era: The Indian perspective.Indian J Gastroenterol. 2017 May;36(3):163-173. doi: 10.1007/s12664-017-0757-1. Epub 2017 Jun 23. Indian J Gastroenterol. 2017. PMID: 28643273 Review.
-
TONEFACT: Can even advanced hemorrhoids be treated without surgery? A paradigm shift in the management of hemorrhoids.World J Gastrointest Surg. 2025 Jul 27;17(7):107099. doi: 10.4240/wjgs.v17.i7.107099. World J Gastrointest Surg. 2025. PMID: 40740911 Free PMC article. Review.
-
Indian consensus on chronic constipation in adults: A joint position statement of the Indian Motility and Functional Diseases Association and the Indian Society of Gastroenterology.Indian J Gastroenterol. 2018 Nov;37(6):526-544. doi: 10.1007/s12664-018-0894-1. Epub 2019 Jan 8. Indian J Gastroenterol. 2018. PMID: 30617919 Free PMC article.
-
Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD003460. doi: 10.1002/14651858.CD003460.pub3. Cochrane Database Syst Rev. 2011. PMID: 21833945 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical